靶向肝癌抗肿瘤疫苗临床研究进展  

Clinical research progress of targeted anti-tumoRvaccines foRhepatocellulaRcarcinoma

作　　者：吴许军 李文阳 张甲戌 WU Xujun;LI Wenyang;ZHANG Jiaxu(Affiliated Hospital of Gansu Medical College,Pingliang 744000,China)

机构地区：[1]甘肃医学院附属医院,甘肃平凉744000 [2]河西学院医学院,甘肃张掖734000 [3]甘肃奥林贝尔生物科技集团甘肃省生物抗菌肽工程实验室,甘肃张掖734000

出　　处：《陕西医学杂志》2022年第12期1611-1613,1617,共4页Shaanxi Medical Journal

基　　金：甘肃省科技计划项目(21CX6NG298)。

摘　　要：抗肿瘤疫苗是癌症免疫疗法的一种。由于癌细胞表面高表达多种癌症相关抗原分子,利用这类分子可激活树突状细胞抗原呈递,激活辅助性T细胞和细胞毒性T细胞的免疫响应,从而清除相应的癌细胞。抗肿瘤疫苗在黑色素瘤、白血病等癌症的临床研究中取得了很好的效果。现就基于常见肝癌相关抗原如甲胎蛋白(AFP)、磷脂酰肌醇蛋白聚糖3(GPC3)、多药耐药相关蛋白3(MRP3)、癌症-睾丸抗原(CTA)设计的靶向肝癌的抗肿瘤疫苗的临床研究进行综述。Anti-tumoRvaccines are a type of canceRimmunotherapy.Due to the high expression of a variety of cancer-related antigen molecules on the surface of canceRcells,the use of such molecules can activate dendritic cell antigen presentation and activate the immune response of helpeRT cells and cytotoxic T cells,thereby eliminating the corresponding canceRcells.Anti-tumoRvaccines have achieved good results in clinical studies of melanoma,leukemia and otheRcancers.This article reviews the clinical studies of anti-tumoRvaccines targeting liveRcanceRbased on common liveRcancer-associated antigens such as alpha-fetoprotein(AFP),phosphatidylinositol proteoglycan 3(GPC3),multidrug resistance-associated protein 3(MRP3)and cancer-testis antigen(CTA).

关 键 词：肝癌 抗肿瘤疫苗 甲胎蛋白 磷脂酰肌醇蛋白聚糖3 多药耐药相关蛋白3 癌症-睾丸抗原 

分 类 号：R735.7[医药卫生—肿瘤]